All In Biotech

Drug Trial Radar · NCT07181265

Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects

A Single-center, Non-randomized, Open-label, Self-controlled Phase I Drug-drug Interaction Clinical Study to Evaluate the Pharmacokinetics of JMKX003142 With Amiodarone, and Febuxostat in Chinese Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Apr 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

  • Amiodarone Hydrochloride TabletsDrug

    Cohort 1: The intervention is for study of drug drug interaction of JMKX003142 when administered with Amiodarone

  • Febuxostat TabletsDrug

    Cohort 2: The intervention is for study of drug drug interaction of JMKX003142 when administered with Febuxostat Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax,ssTime frame: up to 7 days
  2. AUC0-tauTime frame: up tp 7 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.